Clinical efficacy and safety of ixazomid-based treatment for relapsed or refractory multiple myeloma
-
摘要: 目的:探讨伊沙佐米治疗复发难治性多发性骨髓瘤的临床疗效及安全性。方法:收集2018年4月—2020年10月在我院接受以伊沙佐米为基础方案化疗的41例复发或难治性多发性骨髓瘤患者的临床资料,对治疗后反应率及相关不良事件进行分析。结果:所有患者接受平均3个疗程含伊沙佐米的方案化疗,总体反应率为53.66%(22/41),获得非常好的部分缓解及以上的比率为24.39%(10/41)。既往接受过二线以上治疗、ISS分期Ⅲ期、肾功能不全及细胞遗传学高危的患者总体反应率较低(P<0.05)。中位随访22个月,患者中位无进展生存时间为12个月,中位总生存时间为16个月。主要不良事件包括血小板减少(4.9%)、恶心(12.2%)、呕吐(4.9%)、皮疹、带状疱疹等,无周围神经病变发生或加重,大多为Ⅰ~Ⅱ级,对症支持治疗后均好转。结论:伊沙佐米对部分复发或难治性多发性骨髓瘤患者安全有效,值得在临床上应用。Abstract: Objective: To investigate the clinical efficacy and safety of ixazomib in the treatment of relapsed or refractory multiple myeloma.Methods: The clinical data of 41 patients with relapsed or refractory multiple myeloma who received ixazomib-based chemotherapy in our hospital from April 2018 to October 2020 were analyzed, and the response rate and related adverse events after treatment were analyzed.Results: All patients received an average of three courses of chemotherapy containing ixazomib. The overall response rate was 53.66%(22/41), and the rate of very good partial remission and above was 24.39%(10/41). Patients with more than second-line treatment, or ISS stage Ⅲ, or renal insufficiency, or cytogenetics in high-risk patients showed a significantly lower overall response rate(P<0.05). With a median follow-up of 22 months, the median progression free survival and the median overall survival were 12 months and 16 months. The main adverse events included thrombocytopenia(4.9%), nausea(12.2%), vomiting(4.9%), rashes, herpes zoster, etc. Peripheral neuropathy was not occurred or aggravating, mostly gradeⅠ-Ⅱ, suit the support were all improved after treatment.Conclusion: Ixazomib is safe and effective in patients with relapsed or refractory multiple myeloma and is worthy of clinical application.
-
Key words:
- multiple myeloma /
- ixazomib /
- efficacy /
- safety
-
-
[1] Laubach J,Garderet L,Mahindra A,et al.Management of relapsed multiple myeloma:recommendations of the International Myeloma Working Group[J].Leukemia,2016,30(5):1005-1017.
[2] Moreau P,Masszi T,Grzasko N,et al.Oral Ixazomib,Lenalidomide,and Dexamethasone for Multiple Myeloma[J].N Engl J Med,2016,374(17):1621-1634.
[3] Richardson PG,Zweegman S,O'Donnell EK,et al.Ixazomib for the treatment of multiple myeloma[J].Expert Opin Pharmacother,2018,19(17):1949-1968.
[4] 中国医师协会血液科医师分会,中华医学会血液学分会,中国医师协会多发性骨髓瘤专业委员会.中国多发性骨髓瘤诊治指南(2017年修订)[J].中华内科杂志,2017,56(11):866-870.
[5] Kumar S,Paiva B,Anderson KC,et al.International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma[J].Lancet Oncol,2016,17(8):e328-e346.
[6] Chen AP,Setser A,Anadkat MJ,et al.Grading dermatologic adverse events of cancer treatments:The Common Terminology Criteria for Adverse Events Version 4.0[J].J Am Acad Dermatol,2012,67(5):1025-1039.
[7] Xie J,Wan N,Liang Z,et al.Ixazomib-the first oral proteasome inhibitor[J].Leuk Lymphoma,2019,60(3):610-618.
[8] 高晓云,马艳萍.血清B细胞成熟抗原在多发性骨髓瘤中的研究现状[J].临床血液学杂志,2020,33(5):368-371.
[9] Hou J,Jin J,Xu Y,et al.Randomized,double-blind,placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma:China Continuation study[J].J Hematol Oncol,2017,10(1):137.
[10] Kumar SK,LaPlant BR,Reeder CB,et al.Randomized phase 2trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib[J].Blood,2016,128(20):2415-2422.
[11] 贺艳娟,张凯旋,邹浪,伊沙佐米治疗多发性骨髓瘤的临床研究[J].中南大学学报(医学版),2020,45(3):322-327.
[12] Tzogani K,Florez B,Markey G,et al.European Medicines Agency review of ixazomib(Ninlaro)for the treatment of adult patients with multiple myeloma who have received at least one prior therapy[J].ES-MO Open,2019,4(5):e000570.
[13] 许晓东,曹俊杰,庄贤栩,等.伊沙佐米治疗难治复发多发性骨髓瘤临床疗效及相关毒副反应研究[J].临床血液学杂志,2020,33(3):205-207.
[14] 梅舒翀,余莉,陈国安.多发性骨髓瘤免疫治疗研究进展[J].临床血液学杂志,2019,32(9):724-728.
-
计量
- 文章访问数: 209
- PDF下载数: 352
- 施引文献: 0
下载: